FIG 6.

Filovirus GP-specific IgG ELISA titer responses in BALB/c mice immunized with monovalent and trivalent rVSV-N4CT1 FiloGP1 vaccines. At study weeks 0 and 4 (arrows), BALB/c mice were immunized i.m. with 1 × 10⁷ PFU of each monovalent rVSV-N4CT1 FiloGP1 vaccine or with 3 × 10⁷ PFU of the trivalent rVSV-N4CT1 pan-FiloGP1 vaccine. At study weeks 0, 2, 6, and 10, sera were collected and tested for EBOV GP-specific (A), SUDV GP-specific (B), and MARV GP-specific (C) IgG responses by ELISA. The data represent the average log-transformed filovirus GP-specific IgG endpoint titers, with the standard errors of the mean indicated by the error bars. *, statistically significant difference (P < 0.05) between the monovalent rVSV-N4CT1 FiloGP1- and trivalent rVSV-N4CT1 pan-FiloGP1-immunized mice.